Research programme: antifungals - CEPTYRAlternative Names: BAP-100
Latest Information Update: 09 Jul 2007
At a glance
- Originator CEPTYR
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Mycoses
Most Recent Events
- 12 Jul 2004 Preclinical trials in Mycoses in USA (unspecified route)